RxDoctor Payments Data

George Silis, MD

Internal Medicine · Alexandria, VANPI 1003977422

Payments from drug & device makers

$10,596in general payments, 2019–2025

Across 563 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Pfizer$1K
  • Novo Nordisk$877
  • Amgen$757
  • Merck$668
  • Lilly USA, LLC$655
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$10,53499%
  • Education$280%
  • Entertainment$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,596 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$290,904
Medicare patients
597
Services billed
3,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban213$113,057
JardianceEmpagliflozin67$54,161
JulucaDolutegravir/Rilpivirine11$40,729
XareltoRivaroxaban39$35,510
FarxigaDapagliflozin Propanediol43$27,077
EntrestoSacubitril/Valsartan22$24,553
OzempicSemaglutide19$23,376
MounjaroTirzepatide16$21,101
Breo ElliptaFluticasone/Vilanterol40$18,295
JanuviaSitagliptin Phosphate28$10,605
CreonLipase/Protease/Amylase14$10,460
Repatha SureclickEvolocumab11$8,575
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,081
MyrbetriqMirabegron14$4,492
Atorvastatin Calcium361$4,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,354$113,057213 claims
Boehringer IngelheimJardiance$118$54,16167 claims
Johnson & JohnsonXarelto$284$35,51039 claims
AstraZenecaFarxiga, Symbicort$1,389$30,29956 claims
NovartisEntresto$284$24,55322 claims
Novo NordiskOzempic$877$23,37619 claims
Lilly USA, LLCMounjaro$655$21,10116 claims
GSKBreo Ellipta$284$18,29540 claims
AbbVieCreon, Synthroid$483$12,97441 claims
MerckJanuvia$668$10,60528 claims
Astellas Pharma US IncMyrbetriq$251$4,49214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →